Company Ligand Pharmaceuticals Incorporated

LGND

US53220K5048

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Ratings for Ligand Pharmaceuticals Incorporated

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
68.53 ^USD	-5.44%		-14.09%	-4.05%

Apr. 08	Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	CI
Apr. 03	Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer	CI

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

Number of employees: 58

USD in Million	2022	Weight	2023	Weight	Delta
Biopharmaceutical 100.0 %	196	100.0 %	131	100.0 %	-33.09%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	196	100.0 %	131	100.0 %	-33.09%

Managers	Title	Age	Since
Todd Davis CEO	Chief Executive Officer	63	07-02-28
Octavio Espinoza DFI	Director of Finance/CFO	53	22-10-31
Matthew Korenberg PSD	President	49	15-08-05
Andrew Reardon LAW	General Counsel	49	21-12-31
Richard B. Baxter PRN	Corporate Officer/Principal	-	Feb. 19
Karen Reeves PRN	Corporate Officer/Principal	-	Feb. 19
Audrey Warfield-Graham HRO	Human Resources Officer	-	94-11-30

Members of the board	Title	Age	Since
John W. Kozarich CHM	Chairman	74	03-02-28
John LaMattina BRD	Director/Board Member	74	11-01-31
Stephen Sabba BRD	Director/Board Member	64	08-08-03
Jason Aryeh BRD	Director/Board Member	56	06-09-26
Todd Davis CEO	Chief Executive Officer	63	07-02-28
Nancy Ryan Gray BRD	Director/Board Member	64	17-08-17
Martine Zimmermann BRD	Director/Board Member	55	23-09-25
Jason Haas BRD	Director/Board Member	56	22-06-28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	17,705,287	16,655,688 ( 94.07 %)	0	94.07 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 15.93 %	2,820,506	15.93 %	206 M $
Vanguard Fiduciary Trust Co. 10.60 %	1,876,514	10.60 %	137 M $
Janus Henderson Investors US LLC 7.586 %	1,343,154	7.586 %	98 M $
Macquarie Investment Management Business Trust 5.577 %	987,354	5.577 %	72 M $
STATE STREET CORPORATION 3.774 %	668,284	3.774 %	49 M $
Dimensional Fund Advisors LP 3.735 %	661,298	3.735 %	48 M $
Stephens Investment Management Group LLC 3.725 %	659,434	3.725 %	48 M $
St. Denis J. Villere & Co. LLC 2.418 %	428,051	2.418 %	31 M $
John Higgins 2.359 %	417,695	2.359 %	31 M $
Geode Capital Management LLC 2.094 %	370,815	2.094 %	27 M $

Name	Equities	%	Valuation
Ancora Alternatives LLC -	12,000	-	48 $

Name	Equities	%	Valuation
VIKING THERAPEUTICS, INC. 3.31%	3,616,077	3.31%	296,518,314 $

Ligand Pharmaceuticals, Inc.

555 Heritage Drive Suite 200

33458, Jupiter

+858 550 7500

http://www.ligand.com

address Ligand Pharmaceuticals Incorporated(LGND)

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

68.53 USD

Average target price

116.8 USD

Spread / Average Target

+70.44%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
LIGAND PHARMACEUTICALS INCORPORATED	-4.05%	1.21B
ELI LILLY AND COMPANY	+25.46%	659B
NOVO NORDISK A/S	+25.38%	557B
JOHNSON & JOHNSON	-4.86%	359B
MERCK & CO., INC.	+16.44%	322B
ABBVIE INC.	+8.34%	297B
ASTRAZENECA PLC	+6.13%	215B
NOVARTIS AG	+2.93%	210B
ROCHE HOLDING AG	-7.65%	200B
PFIZER, INC.	-8.79%	149B

Other Pharmaceuticals